Biocon, incorporated at Bangalore, India in 1978, is a fully integrated biotechnology enterprise focused on biopharmaceuticals, custom research, clinical research and enzymes. The company was promoted as a joint venture with Ireland-based MNC Biocon Biochemicals. Later, Unilever acquired Biocon Biochemical`s stake in 1995, but sold it to the current promoters in 1999. The company has its facilities at Hebbagodi and Bommasandra, Bangalore district, Karnataka and is engaged in manufacture of biotechnological products in the pharmaceutical and enzyme sectors through fermentation based technology. Biocon continues to be the only Indian company to have USFDA qualification for Lovastatin. FDA has inspected and accepted Biocon`s facilities for Simvastatin, Pravastatin, Pioglitazone HCl, Lovastatin (submerged fermentation). It has commercialized human insulin (rDNA) based on Pichia expression system. Biocon has also submitted the `Drug Master` file for the same with USFDA. The company has a a couple of subsidiary companies namely, Syngene International, which is into chemistry and molecular-based custom research services in early stage drug discovery and development and Clinigene International, which offers longitudinal research in diabetes with comprehensive services in drug development and clinical trials. Also, the company has invested in a joint venture called Biocon Biopharmaceuticals. The company plans to focus on monoclonal antibodies as part of Biocon`s fermentation business, research areas of new drug discovery, clinical development of existing pipeline of biologicals, strategic collaborations and continued R&D capabilities in biologics.
You
should Trade Less But Trade Accurately & this is Achieved with our Tip.
